Leading the research and development efforts is Rebecca Taylor, a prominent mechanical engineering professor at Carnegie Mellon University, supported by co-investigator Burak Ozdoganlar. Their expertise in mechanical engineering converges with the cutting-edge fields of synthetic biology and nucleic acid nanotechnology to forge a novel cancer detection platform. The project integrates an innovative orally administered pill embedded with engineered tumor-targeting sensors alongside a highly sensitive urine analysis device intended for use in the convenience of patients’ homes.

Unlike traditional cancer detection methods that frequently require invasive biopsies, complex imaging, or hospital visits, this technology leverages biological and chemical signatures of tumors. The pill contains biosensors calibrated to detect microenvironmental cues characteristic of malignant cells, namely hypoxia (low oxygen levels), increased acidity, and elevated lactate concentrations, which are well-established hallmarks of tumor physiology. These sensors respond dynamically to such conditions by releasing synthetic molecular reporters that are specifically tailored to signify the presence of cancer and identify the tumor’s tissue of origin.

Following ingestion, the biosensors transit the body’s vascular system and tissue compartments to home in on suspicious microenvironments, reacting only where pathological conditions prevail. Once activated, the sensors emit synthetic reporter molecules that enter the body’s excretory pathway and accumulate in urine. This non-invasive excretion route enables an accessible biological sample to be collected effortlessly by patients, circumventing the need for clinical blood draws or imaging modalities.

The accompanying screening device, crafted as a compact diagnostic tool, employs CRISPR-Cas-based biosensors to detect the RNA reporters within the urine sample. This device translates reporter presence into measurable electrical signals, utilizing nucleic acid recognition and amplification techniques to ensure high sensitivity and specificity. The multiplexed platform is designed to delineate not only the existence of cancerous lesions but also their anatomical origins, empowering personalized surveillance and early intervention strategies.

Beyond detection, this system connects wirelessly to smartphones, delivering real-time results paired with comprehensive educational content and tailored pathways for medical follow-up. This integration exemplifies patient-centric innovation by combining molecular diagnostics with digital health technologies to enhance accessibility, engagement, and adherence.

The significance of this technology lies not only in its scientific novelty but also in its potential scalability and affordability. The goal is to commercialize this multi-cancer detection kit at a retail price below $100, rendering early cancer screening accessible to a vast population. Affordable widespread screening presents an unprecedented opportunity to reduce cancer-related mortality by enabling interventions at the earliest stages when treatments are most effective and least invasive.

This project’s commercial translation is facilitated by Ginkgo Bioworks, the selected commercialization partner, which brings expertise in synthetic biology and bioengineering to the table. Their involvement ensures the seamless scaling of complex biologics and molecular devices from the lab bench to consumer-ready medical products.

The collaboration extends beyond Carnegie Mellon, drawing on the diverse knowledge and experience of partners at the University of Pittsburgh, the University of Massachusetts Amherst, KU Leuven, and industry leaders such as Velentium Medical, Clinical Research Strategies, and Platypus Bio. This convergence of academia and industry underscores the multi-disciplinary nature required to tackle the complexities of cancer diagnostics.

The technological approach is visionary, combining recent advances in synthetic biology—which enables the design of living systems to perform novel functions—and nucleic acid nanotechnology, which manipulates RNA and DNA molecules for highly sensitive detection. Importantly, the use of CRISPR-Cas systems in this context exemplifies the cutting edge of molecular diagnostics, leveraging programmable nucleases to detect very specific sequences of synthetic RNA reporters efficiently.

As Rebecca Taylor emphasizes, this dual-function approach promises an unprecedented degree of precision, turning the human body into a living sensor array that can reveal hidden tumors before they manifest clinically. The vision is to make early cancer detection as simple as administering a pill and collecting a urine sample at home, disrupting current paradigms of reactive, symptom-driven diagnostics.

Burak Ozdoganlar adds that this innovation is not only a scientific leap but a humanitarian imperative, aiming to democratize cancer screening globally. Making reliable, easy-to-use diagnostics widely available empowers individuals to monitor their health proactively, reducing the incidence of advanced-stage cancer diagnoses that are costly and devastating.

Moving forward, the team intends to advance this technology through rigorous human clinical trials to validate safety, efficacy, and user experience. Success in clinical validation will pave the way for regulatory approvals and mass production, culminating in a product poised to save millions of lives worldwide by shifting the detection window upward—ensuring intervention when cancers are most treatable.

In conclusion, this pioneering project represents a powerful fusion of engineering, synthetic biology, and digital health applied to one of humanity’s most pressing medical challenges. By harnessing bioengineered sensors, nucleic acid nanotechnology, and CRISPR-based diagnostics, the team is charting a new course toward affordable, patient-friendly, and life-saving cancer screening that could revolutionize how healthcare is delivered and experienced.

Subject of Research: Early cancer detection technology leveraging synthetic biology and nucleic acid nanotechnology for non-invasive, at-home cancer screening via urine analysis.

Article Title: Transforming Early Cancer Detection with Synthetic Biology: Carnegie Mellon-Led Team Develops At-Home Urine Test for 30+ Stage 1 Cancers

News Publication Date: Not specified

Web References:
– ARPA-H POSEIDON program: https://arpa-h.gov/explore-funding/programs/poseidon
– Carnegie Mellon University: http://cmu.edu/
– CMU College of Engineering: http://engineering.cmu.edu/

Keywords: Cancer screening, Oncology, Urine diagnostics, Synthetic biology, Nanotechnology, CRISPR-Cas technology, Early cancer detection, Multi-cancer detection kit, At-home medical device

Shi’s work is situated within the Southern Polytechnic College of Engineering and Engineering Technology (SPCEET) at Kennesaw State University, where engineering principles merge with medical science to tackle complex biological problems. Supported by a National Science Foundation (NSF) grant, Shi’s team is pioneering the creation of patient-specific “digital twins” of the human stomach—sophisticated virtual models that replicate both the physical structure and electrical dynamics of this vital organ. These digital twins are crafted using an integrative approach that combines advanced medical imaging techniques, biomechanical tissue testing, and high-fidelity computational modeling.

At the core of this research lies the hypothesis that conventional diagnostic methods may miss critical changes occurring at the microscopic mechanical level within gastrointestinal tissues. Despite normal appearances on traditional endoscopy or imaging, the stomach may harbor subtle stiffness variations or disruptions in its intrinsic electrical signaling that profoundly impact its motility and function. Shi’s models incorporate these nuanced biomechanical and electrophysiological properties to create a dynamic simulation environment that parallels the real physiological behavior of the stomach with remarkable precision.

To build these models, Dr. Shi’s research collaborates closely with clinicians at Emory University, who provide a rich dataset that includes CT scans, endoscopic images, and a specialized diagnostic measurement called manometry. Manometry gauges pressure fluctuations and tissue deformation throughout the stomach and esophagus during digestion, giving unique insights into the organ’s biomechanical activity. Using this data, Shi’s lab runs a battery of mechanical tests—such as tensile and biaxial assays—to quantify tissue elasticity, stiffness, and response to physiological loading conditions.

“Two stomachs may appear identical, but their biomechanical properties could be worlds apart,” Shi explains. His experiments reveal how variations in tissue elasticity affect the contraction patterns and peristaltic waves essential for moving food through the digestive system. The integration of electrical signaling data into the modeling framework further enhances the fidelity of these digital twins. By simulating electrical wave propagation and its influence on tissue movement, the model captures critical feedback loops between the stomach’s mechanical and electrical subsystems.

This innovative approach holds tremendous potential not just for diagnosis but also for personalized therapeutic interventions. Current clinical evaluations provide limited predictive power when it comes to treatment efficacy or disease progression. However, digital twins offer a virtual testbed to simulate how varied therapeutic strategies—ranging from pharmacological to surgical—might alter gastric behavior. This paves the way toward precision medicine strategies where interventions can be optimized on a case-by-case basis, reducing trial-and-error and improving patient outcomes.

SPCEET Dean Lawrence Whitman emphasizes the transformative nature of this research, noting that it represents a symbiotic fusion of engineering, computational science, and clinical medicine. “Dr. Shi’s work exemplifies how multidisciplinary collaboration can lead to breakthroughs that improve lives,” Whitman remarks. The research is not confined to the stomach alone; Shi envisions extending his modeling techniques to the entire gastrointestinal tract, from the esophagus through the intestines, encompassing complex interactions such as the brain-gut axis, which influences digestion, mood, and immunity.

Incorporating machine learning algorithms is another frontier Shi plans to explore, aiming to accelerate the analysis and predictive capabilities of these models. By leveraging pattern recognition and data-driven insights, the research will evolve from static simulations to adaptive virtual platforms capable of real-time diagnostics. Drawing on Shi’s prior success modeling the heart, uterus, and cervix, this work uses analogous computational methods to expedite development and accuracy.

A unique aspect of this project is its immersive training environment for emerging scientists and engineers. Currently, Shi mentors Ph.D. students actively contributing to experimental mechanics and modeling, providing invaluable hands-on experience. “The interdisciplinary nature of this research enriches our understanding far beyond traditional engineering,” notes Yue Li, a doctoral candidate involved in the project. The collaboration fosters skill development in mechanical testing, data integration, and computational simulation, preparing students for careers at the nexus of engineering and biomedicine.

Emerging from the Intelligent Biomechanics lab on KSU’s Marietta Campus, this undertaking exemplifies how technological innovation can address healthcare’s persisting enigmas. By constructing detailed digital surrogates of the stomach, Shi’s team is opening new vistas in comprehending GI disorders that have long eluded accurate detection. Their comprehensive approach, uniting biomechanics with electrophysiology and medical imaging, propels the ambition of personalized digestive healthcare into a new era.

As the digital twin technology matures, it promises to influence clinical workflows significantly, reducing diagnostic ambiguity and enhancing treatment precision. Future integration with wearable sensors and real-time imaging could enable continuous monitoring of gastrointestinal function, offering unprecedented insight into disease onset and progression. Ultimately, Lei Shi’s pioneering work positions mechanical engineering at the forefront of transforming digestive health, embodying the next generation of intelligent medical technology.

Subject of Research: Development of patient-specific digital twins of the human stomach for improved diagnosis and treatment of gastrointestinal disorders.

Article Title: Transforming Gastrointestinal Healthcare: Engineering Virtual Twins of the Human Stomach

News Publication Date: [Not provided]

Web References:

• Kennesaw State University Southern Polytechnic College of Engineering and Engineering Technology: https://www.kennesaw.edu/spceet/index.php
• Lei Shi’s Lab Homepage: https://facultyweb.kennesaw.edu/lshi/index.php

Image Credits: Credit: Darnell Wilburn / Kennesaw State University

Keywords: Gastrointestinal disorders, digestive disorders, gastrointestinal tract, medical imaging, diseases and disorders, gastroenteritis